NeOnc Technologies reported a widened net loss for the second quarter 2026 as it increased investments in its clinical pipeline. The company is currently approaching a significant catalyst, with topline Phase 2a data for its lead candidate NEO100 in high-grade glioma scheduled for presentation on August 12, 2026.
Key Highlights
- Research and development expenses increased nearly fourfold to $2.6 million, driven by the expansion of clinical trial sites and drug-product manufacturing.
- The company secured UAE IND approvals for both NEO100 and NEO212, facilitating an international clinical development pathway alongside U.S. programs.
- Liquidity remains a critical factor with $2.0 million in cash as of June 30, 2026, supported by an undrawn $10.0 million related-party line of credit and $44.5 million available via an equity purchase facility.